Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
34.80
-35.39 (-50.42%)
At close: Dec 31, 2025, 4:00 PM EST
34.70
-0.10 (-0.29%)
After-hours: Dec 31, 2025, 5:02 PM EST
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Corcept Therapeutics stock have a consensus rating of "Buy" and an average price target of $130.2, which forecasts a 274.14% increase in the stock price over the next year. The lowest target is $95 and the highest is $150.
Price Target: $130.2 (+274.14%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Initiates $95 | Hold | Initiates | $95 | +172.99% | Dec 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +316.67% | Nov 25, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +316.67% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +316.67% | Oct 10, 2025 |
Financial Forecast
Revenue This Year
836.81M
from 675.04M
Increased by 23.96%
Revenue Next Year
1.20B
from 836.81M
Increased by 43.40%
EPS This Year
0.99
from 1.23
Decreased by -19.56%
EPS Next Year
1.10
from 0.99
Increased by 11.08%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 873.3M | 1.5B | ||||
| Avg | 836.8M | 1.2B | ||||
| Low | 791.7M | 994.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 29.4% | 74.2% | ||||
| Avg | 24.0% | 43.4% | ||||
| Low | 17.3% | 18.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.24 | 2.98 | ||||
| Avg | 0.99 | 1.10 | ||||
| Low | 0.79 | -0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.7% | 201.4% | ||||
| Avg | -19.6% | 11.1% | ||||
| Low | -35.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.